09939 KINTOR PHARMA-B
- 1.160
- -0.020-1.69%
KINTOR PHARMA-B News
Kintor Pharmaceutical Completed 1st Subject Enrolment in a Phase 2 Clinical Trial of Acne Drug in China
Kintor Pharmaceutical (HKG:9939) completed the first subject enrolment in a phase II clinical trial of GT20029 in China for the treatment of acne, a Monday filing on the Hong Kong bourse. The phase II
Kaituo Pharmaceutical (09939) rose 5%. Its self-developed KX-826 receives INCI naming.
Kaituo Pharma (09939) saw its stock price rise after its self-developed KX-826 received INCI naming. As of press time, the stock rose 5% to HK$1.26 with a turnover of HK$3.1889 million. According to the announcement, KX-826, its self-developed drug, has recently been approved by the International Nomenclature Committee for Cosmetic Ingredients (INCI) for review and will be officially approved as Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoim.
Kintor Pharma Receives Standard Cosmetic Ingredient Name for KX-826 Product
Kintor Pharma (HKG:9939) obtained approval from the International Cosmetic Ingredient Nomenclature Committee for its KX-826 product for cosmetics, according to a Tuesday filing with the Hong Kong Stoc
KX-826 of Kaiyao Pharmaceutical-B (09939) has been named by INC.
Kaituo Pharmaceutical-B (09939) announced that its self-developed KX-826 has recently internationalized...
Kintor Pharmaceutical's Androgenic Alopecia Drug Gets Regulatory Nod; Share Prices Shoot 10%
Kintor Pharmaceutical (HKG:9939) said its androgenic alopecia drug KX826 tincture 1.0% was approved for use by China's National Medical Products Administration (NMPA), according to a Friday filing on
Kaituo Pharmaceutical-B (09939.HK): KX-826 tincture 1.0% clinical trial for androgenic alopecia in adult Chinese men approved by NMPA
Gelonghui May 24 | Kaituo Pharmaceutical-B (09939.HK) announced that its self-developed clinical trial of 1.0% KX-826 tincture to treat androgenic alopecia (“AGA”) in adult Chinese men (“this clinical trial”) has recently been approved by the National Drug Administration (“NMPA”) to evaluate the efficacy and safety of KX-826 tincture 1.0% topical treatment for male AGA patients in China. The company's pre-clinical study showed that compared to the 0.5% dosage form of KX-826 tincture used in the previous phase III clinical trial, this tincture was 1.0%
Changes in Hong Kong stocks | The collective decline in pharmaceutical stocks will improve the quality and expansion of pharmaceutical procurement, which is expected to form a national alliance for procurement
Pharmaceutical stocks fell collectively today. As of press release, Luye Pharmaceuticals (02186) fell 7.72% to HK$2.75; Kaituo Pharmaceutical-B (09939) fell 7.35% to HK$1.26; Zhongsheng Pharmaceuticals (01177) fell 5.75% to HK$2.95; and Cinda Biotech (01801) fell 4.61% to HK$38.3.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
開拓藥業-B：年報 2023
Kaituo Pharmaceutical-B (09939): Restitution of land use rights located in Pinghu City, Zhejiang Province, China
Kaituo Pharmaceutical-B (09939) issued an announcement. On April 25, 2024, the seller Kaituo Pharmaceutical (Zhejiang) had...
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment
Kintor Pharmaceutical (HKG:9939) said it completed the Phase II clinical trials for its Androgenic Alopecia treatment GT20029 in China, according to a Sunday filing on the Hong Kong bourse. The pharma
Changes in Hong Kong stocks | Pioneer Pharmaceutical-B (09939) opens nearly 15% GT20029 to treat male hair loss, China's phase II clinical trial reached the main end
Kaituo Pharmaceutical-B (09939) rose by nearly 15%. As of press release, it rose 14.94% to HK$1, with a turnover of HK$81,000.
Pioneer Pharmaceutical-B (09939): GT20029 Chinese phase II clinical trial to treat male hair loss reached the main end
Zhitong Finance App News, Kaituo Pharmaceutical-B (09939) issued an announcement. The board of directors of the company is pleased to announce that the Chinese phase II clinical trial for topical treatment of androgenic alopecia in men with a novel proteolytic chimeric compound targeting androgen receptors has reached the main research end. The results are statistically significant and clinically significant, and the safety and tolerability are good. GT20029 Based on the results of this phase II clinical trial, the company will actively deploy clinical strategies for GT20029 follow-up, such as conducting a phase III clinical trial of male hair loss in China and US II
Develop the pharmaceutical industry's 2023 performance: explore Pico's multi-channel commercialization path and dig deeper into multi-pipeline R&D and commercial value
SUZHOU, March 29, 2024/PRNewswire/ -- On March 29, 2024, Beijing time, Kaituo Pharmaceutical (stock code: 9939.HK), a biopharmaceutical company focused on the development and industrialization of potential pioneers and best-in-class innovative drugs, announced recent business highlights and annual results for the year ending December 31, 2023. 2023 Annual Results Overview Business Overview Pico Dual Core Products Global Clinical Research and Development Continues to Advance Multiple Pipelines Reveal the Value of R&D and Commercial Cooperation Multiple Research Results Selected for Important Academic Conferences and Financial Overview Funding in Core Journals
Kaituo Pharmaceutical-B (09939) announced its 2023 annual results, with a net loss of 1.06 billion yuan, an increase of 11.2% over the previous year
Kaituo Pharmaceutical-B (09939) announced the results for the year ended December 31, 2023, and the Group has not approved the entry...
KINTOR PHARMA-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Kaituo Pharmaceutical-B (09939.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 15 | Kaituo Pharmaceutical-B (09939.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
KINTOR PHARMA-B: DATE OF BOARD MEETING
Kaituo Pharmaceutical-B (09939) published research results on c-MYC-targeting molecular gum compounds in the Nature sub-journal
The article mainly analyzes the mechanism of action of MYC in inducing resistance to CDK4/6 inhibitors by promoting PRB1 degradation, and suggests that the c-Myc degrading agent a80.2hcl can enhance the therapeutic effect of CDK4/6 inhibitors.
Study of Kintor's C-Myc Degrader Published in Subsidiary Journal of Nature
SUZHOU, China, March 14, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological
Analysis
Price Target
No Data
